Guidelines for the diagnosis and treatment of malignant pleural mesothelioma - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …

Purpose To provide evidence-based recommendations to practicing physicians and others
on the management of malignant pleural mesothelioma. Methods ASCO convened an …

Refer all patients with a chest X-ray suggestive of MPM urgently (via the 2-week wait
suspected cancer pathway in England and Wales). Consider referral for further investigation …

The asbestos‐related disorders (ARDs) are currently of significant occupational and public
health concern. Asbestos usage has been banned in most developed countries, but …

Introduction Advanced thymoma (stage III and IV) is difficult to detect by computed
tomography (CT), yet it is important to distinguish between early (stage I and II) and …

Introduction: The staging system for malignant pleural mesothelioma is controversial. To
revise this system, the International Association for the Study of Lung Cancer Staging …

The malignant pleural mesothelioma is a very aggressive tumor which is arising from
mesothelial cells and is associated with asbestos exposure. It is a heterogeneous cancer …

Background There are currently no available biomarkers for advanced pleural
mesothelioma that determine which patients could benefit from a specific chemotherapy …

Purpose Malignant pleural mesothelioma (MPM) is a disease with poor prognosis despite
multimodal therapy but there is variation in survival between patients. Prognostic information …

Peritoneal disease can be caused by a wide spectrum of pathologies. While peritoneal
disease is usually caused by primary or secondary malignancies, benign diseases can …